Iovance Biotherapeutics Inc
Statements
Cash Flow
Iovance Biotherapeutics Inc (IOVA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -61 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -12 | -19 | -17 | -21 | -21 | -18 | -24 | -28 | -32 | -29 | -34 | -42 | -54 | -65 | -37 | -41 | -63 | -62 | -54 | -58 | -54 | -74 | -78 | -64 | -78 | -100 | -94 | -84 | -84 | -122 | -98 | -59 | -73 | -104 | -67 | -79 | -53 | -72 | -61 | -264 | |
| 0.1 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 2.3 | 2.1 | 0.3 | 0.3 | 2.9 | 2.8 | 2.8 | 4.0 | 12 | 5.0 | 5.2 | 5.2 | 5.7 | 5.7 | 7.8 | 9.9 | 9.7 | 9.9 | 11 | 11 | 12 | 11 | 12 | 12 | 13 | 10 | 10 | 45 | |
| 8.6 | 3.1 | 3.3 | 3.3 | 2.6 | 2.8 | 4.1 | 5.2 | 5.5 | 5.2 | 5.8 | 6.4 | 6.6 | 5.4 | 9.4 | 11 | 11 | 10 | 17 | 14 | 19 | 19 | 22 | 22 | 20 | 20 | 16 | 17 | 16 | 14 | 17 | 30 | 31 | 31 | 23 | 15 | 12 | 12 | 11 | 12 | 47 | |
| 8.6 | 3.1 | 3.3 | 3.3 | 2.6 | 2.8 | 4.1 | 5.2 | 5.5 | 5.2 | 5.5 | 6.8 | 7.9 | 7.0 | 9.4 | 11 | 11 | 10 | 17 | 16 | 19 | 19 | 23 | 22 | 20 | 19 | 16 | 16 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2.2 | 0.1 | -1.7 | 2.3 | -2.1 | 1.9 | 4.3 | 1.3 | 0.5 | -3.5 | 1.9 | 6.6 | -0.9 | 2.4 | -7.2 | 14 | 5.0 | -8.9 | -8.7 | 8.4 | 3.8 | 21 | -10 | -6.5 | 11 | 3.0 | -13 | -11 | 5.9 | 12 | -33 | -39 | -13 | -38 | -18 | 9.2 | -8.5 | -7.3 | -13 | -36 | -65 | |
| 0.7 | 0.7 | 0.8 | 0.0 | 0.3 | 0.1 | 0.0 | 0.4 | 0.5 | 0.3 | 0.8 | 1.4 | 1.2 | 3.4 | 0.6 | 5.0 | 18 | 23 | 11 | 9.6 | 9.7 | 7.6 | 11 | 4.6 | 1.4 | 3.0 | 5.7 | 9.5 | 3.6 | 3.5 | 4.2 | 0.4 | 2.3 | 4.2 | 6.2 | 7.5 | 11 | 9.3 | 6.6 | 5.4 | 32 | |
| -17 | 26 | 19 | 25 | 14 | 0.1 | 0.0 | -31 | -149 | -206 | 1.0 | 59 | 3.5 | 27 | 100 | -424 | -53 | 59 | 77 | -159 | 13 | 69 | 87 | 96 | 74 | 0.5 | 153 | -157 | -79 | -73 | -112 | 40 | -49 | 24 | 16 | 14 | 17 | 0.8 | 11 | -74 | -45 | |
| 0.0 | 49 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | -0.3 | 0.0 | -1.2 | 56 | 0.0 | -0.1 | -0.1 | -0.1 | 0.0 | -0.1 | 0.0 | -0.1 | -0.1 | -0.1 | -0.2 | 1.2 | 0.0 | 49 | 164 | 21 | 1.6 | 1.4 | -2.6 | 0.2 | 1.7 | -1.9 | -0.3 | -0.4 | -0.2 | -4.7 | -1.0 | 7.3 | – | – | – | 0.7 | 0.2 | – | 0.9 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.0 | 1.0 | 1.0 | 1.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 0.2 | 0.4 | -0.6 | 56 | 2.9 | 170 | 3.4 | 12 | 239 | 0.0 | 3.4 | 0.7 | 2.1 | 3.8 | 568 | 1.2 | 3.0 | 50 | 164 | 21 | 4.2 | 1.4 | -2.1 | 0.2 | 191 | 258 | 1.0 | 203 | 1.0 | 194 | 153 | 42 | 2.3 | 143 | 13 | 88 | 56 | 94 | 49 | 288 | |
| -8.3 | 14 | 0.4 | 7.2 | 49 | -18 | 152 | -51 | -165 | 1.4 | -28 | 28 | -38 | -25 | 39 | 108 | -92 | -1.0 | 65 | -49 | -24 | 20 | 14 | 16 | 10 | 113 | 312 | -253 | 38 | -153 | -41 | 94 | -65 | -48 | 56 | -40 | 26 | 5.0 | -157 | -191 | -317 | |
| -13 | -13 | -20 | -18 | -22 | -21 | -18 | -24 | -28 | -32 | -30 | -35 | -43 | -57 | -66 | -42 | -58 | -86 | -73 | -64 | -67 | -61 | -85 | -82 | -65 | -81 | -105 | -103 | -88 | -87 | -126 | -99 | -61 | -77 | -110 | -75 | -90 | -62 | -79 | -66 | -296 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.